CN105682653B - 2，4-二硝基苯酚制剂和使用其的方法 - Google Patents

2，4-二硝基苯酚制剂和使用其的方法 Download PDF

Info

Publication number
CN105682653B
CN105682653B CN201480059363.0A CN201480059363A CN105682653B CN 105682653 B CN105682653 B CN 105682653B CN 201480059363 A CN201480059363 A CN 201480059363A CN 105682653 B CN105682653 B CN 105682653B
Authority
CN
China
Prior art keywords
subject
composition
compound
dnp
erdnp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480059363.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN105682653A (zh
Inventor
G·I·舒尔曼
R·J·佩里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52587363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105682653(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yale University filed Critical Yale University
Priority to CN201910726120.2A priority Critical patent/CN110302385A/zh
Publication of CN105682653A publication Critical patent/CN105682653A/zh
Application granted granted Critical
Publication of CN105682653B publication Critical patent/CN105682653B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/06—Phenols the aromatic ring being substituted by nitro groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480059363.0A 2013-08-30 2014-08-29 2，4-二硝基苯酚制剂和使用其的方法 Active CN105682653B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910726120.2A CN110302385A (zh) 2013-08-30 2014-08-29 新型2，4-二硝基苯酚制剂和使用其的方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361872294P 2013-08-30 2013-08-30
US61/872,294 2013-08-30
US201361919003P 2013-12-20 2013-12-20
US61/919,003 2013-12-20
PCT/US2014/053406 WO2015031756A1 (en) 2013-08-30 2014-08-29 Novel 2,4-dinitrophenol formulations and methods using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910726120.2A Division CN110302385A (zh) 2013-08-30 2014-08-29 新型2，4-二硝基苯酚制剂和使用其的方法

Publications (2)

Publication Number Publication Date
CN105682653A CN105682653A (zh) 2016-06-15
CN105682653B true CN105682653B (zh) 2022-10-21

Family

ID=52587363

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480059363.0A Active CN105682653B (zh) 2013-08-30 2014-08-29 2，4-二硝基苯酚制剂和使用其的方法
CN201910726120.2A Pending CN110302385A (zh) 2013-08-30 2014-08-29 新型2，4-二硝基苯酚制剂和使用其的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910726120.2A Pending CN110302385A (zh) 2013-08-30 2014-08-29 新型2，4-二硝基苯酚制剂和使用其的方法

Country Status (5)

Country Link
US (4) US10786466B2 (OSRAM)
EP (1) EP3038611B1 (OSRAM)
JP (4) JP6706204B2 (OSRAM)
CN (2) CN105682653B (OSRAM)
WO (1) WO2015031756A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015031756A1 (en) 2013-08-30 2015-03-05 Yale University Novel 2,4-dinitrophenol formulations and methods using same
EP4306167B1 (en) 2015-01-22 2025-12-24 Mitochon Pharmaceuticals, Inc. Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases
DE102015016801A1 (de) * 2015-12-23 2017-06-29 Christian Windisch Chemotherapeutisches Verfahren zur Behandlung maliger Geschwülste durch "Entkopplung" der oxidativen Phosphorilierung ("Krebsatmung") in aerob glycolysierenden Zellen (Krebszellen)
CN109195589A (zh) 2016-03-07 2019-01-11 米托充制药公司 神经肌肉性、神经变性、自身免疫性、发育性、脑震荡、干眼病和/或代谢性疾病的dnp和dnp前药治疗
WO2018129258A1 (en) 2017-01-06 2018-07-12 Gencia Corporation Novel phenyl derivatives
WO2019217164A1 (en) * 2018-05-09 2019-11-14 Reyoung Corporation Compositions and methods for treating cancer and other diseases
EP3986420A1 (en) 2019-06-18 2022-04-27 Mitopower LLC Nicotinyl riboside compounds and their uses
CN110302154B (zh) * 2019-07-30 2021-09-10 成都医学院 一种2,4-二硝基苯酚脂肪乳及其制备方法和用途
CN110237033A (zh) * 2019-07-30 2019-09-17 成都医学院 一种2,4二硝基苯酚注射液及其制备方法和用途
CN113045428B (zh) * 2019-12-26 2022-04-22 中国农业大学 化合物及其在减脂中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851546A (en) * 1995-06-14 1998-12-22 Council Of Scientific & Industrial Research Polymer composition for controlled release of active ingredients in response to pH, and a process of preparing the same

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2183589A (en) 1939-12-19 Derivatives of compounds of the
CA774573A (en) 1967-12-26 Sehring Richard Derivatives of 2-hydroxy-3,5-dinitrobenzyl alcohol
US1695656A (en) 1927-03-10 1928-12-18 Firm Gehe & Co A G Method of producing narcotica
US3081224A (en) 1959-01-21 1963-03-12 American Cyanamid Co Methods of removing helminths employing halogenated nitrophenols and their derivatives
NL124981C (OSRAM) 1962-12-27 1900-01-01
DE3313905A1 (de) 1983-04-16 1984-10-25 Henkel KGaA, 4000 Düsseldorf Neue 2.4-diaminophenolether als kuppler fuer oxidationshaarfaerbemittel
DE3515339A1 (de) 1985-04-27 1986-10-30 Cassella Ag, 6000 Frankfurt Verfahren zur herstellung von 2,4-dinitrophenylethern
CN1011660B (zh) * 1986-04-23 1991-02-20 吴佩璇 一种含三硝基苯、田螺的药品合成方法
US5078908A (en) 1989-10-02 1992-01-07 Allergan, Inc. Methods for generating chlorine dioxide and compositions for disinfecting
US5169645A (en) 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
EP0753255B1 (en) 1995-07-11 2000-12-20 Nippon Petrochemicals Co., Ltd. Pesticidal compositions comprising diarylalkanes
EP1073693A1 (en) * 1998-04-24 2001-02-07 Eastman Chemical Company Coprecipitation of cellulose esters with functional additives and compositions thus obtainable
US7635722B1 (en) * 1998-07-27 2009-12-22 Saint Jude Pharmaceuticals, Inc. Chemical induced intracellular hyperthermia
US6664297B1 (en) 2000-10-18 2003-12-16 Universidade Federal Do Rio De Janeiro Methods for inhibition and dissolution of amyloidoses by administration of compositions comprising 2,4-dinitrophenol
DE60224293T2 (de) * 2001-09-21 2008-12-11 Egalet A/S Feste dispersionen mit kontrollierter freisetzung von carvedilol
BR0314269A (pt) 2002-09-13 2005-07-26 Cydex Inc Cápsulas contendo composições aquosas de recheio estabilizadas com ciclodextrina derivatizada
ATE468114T1 (de) 2002-11-08 2010-06-15 High Point Pharmaceuticals Llc Sichere chemische entkuppler zur behandlung von fettsucht
US8569356B2 (en) 2005-10-25 2013-10-29 University Of Florida Research Foundation, Inc. Cyclin dependent kinase inhibitors
EP2196453A1 (en) 2008-12-10 2010-06-16 Cellvir Novel substituted aryl derivatives, their process of preparation and their therapeutical uses as anti-HIV agents
WO2011053825A2 (en) * 2009-10-30 2011-05-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for the treatment or prevention of mitochondrial diseases
JP2013209295A (ja) 2010-10-13 2013-10-10 Takeda Chem Ind Ltd ペプチド誘導体
WO2015031756A1 (en) * 2013-08-30 2015-03-05 Yale University Novel 2,4-dinitrophenol formulations and methods using same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851546A (en) * 1995-06-14 1998-12-22 Council Of Scientific & Industrial Research Polymer composition for controlled release of active ingredients in response to pH, and a process of preparing the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics;Sean Marrache et al.;《PNAS》;20121002;第109卷(第40期);16288–16293 *
Sean Marrache et al..Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics.《PNAS》.2012,第109卷(第40期),16288–16293. *

Also Published As

Publication number Publication date
US11883369B2 (en) 2024-01-30
JP2016530279A (ja) 2016-09-29
HK1225607A1 (en) 2017-09-15
US10786466B2 (en) 2020-09-29
US20160199310A1 (en) 2016-07-14
CN105682653A (zh) 2016-06-15
EP3038611B1 (en) 2024-04-17
CN110302385A (zh) 2019-10-08
JP2020002166A (ja) 2020-01-09
JP2021165309A (ja) 2021-10-14
US20220339121A1 (en) 2022-10-27
EP3038611A1 (en) 2016-07-06
US20200352879A1 (en) 2020-11-12
US11433033B2 (en) 2022-09-06
EP3038611A4 (en) 2017-03-29
JP6913137B2 (ja) 2021-08-04
JP7359809B2 (ja) 2023-10-11
JP2023133603A (ja) 2023-09-22
WO2015031756A1 (en) 2015-03-05
JP6706204B2 (ja) 2020-06-03
US20250228793A1 (en) 2025-07-17

Similar Documents

Publication Publication Date Title
CN105682653B (zh) 2，4-二硝基苯酚制剂和使用其的方法
KR101715008B1 (ko) Ｌ―오르니틴 페닐아세테이트를 사용한 문맥압 항진증의 치료 및 간 기능 회복
US10806735B2 (en) Use of neutrophil elastase inhibitors in liver disease
JP6067203B2 (ja) ２−ヒドロキシ−５−フェニル安息香酸誘導体の処方および使用
KR102412997B1 (ko) 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법
US20240238232A1 (en) Compositions and methods for the reduction or treatment of insulin resistance and metabolic conditions
EP2453743B1 (en) N-acetyl cysteine compositions and their use in improving the therapeutic efficacy of acetaminophen
JP2008509145A (ja) 抗糖尿病性経口インスリン−ビグアニドの組み合わせ
KR20190034550A (ko) 간성 뇌병증의 치료 방법
HK1225607B (en) Sustained-release pharmaceutical composition comprising 2,4-dinitrophenol
CA3204811A1 (en) Denatonium salt for use in preventing, preventing progression and treating fatty liver diseases
HK40012204A (en) Treatment of inflammation using l-ornithine phenylacetate
HK40031634A (en) Medicinal composition for preventing or treating secondary hyperparathyroidism under maintenance dialysis
HK1174264B (en) Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant